Jump to content

Red biotechnology

The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

  • Press release - 20/01/2025

    Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process.

  • Press release - 16/01/2025

    Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

  • Press release - 14/01/2025

    If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible.

  • Press release - 13/01/2025

    Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions.

  • Press release - 07/01/2025

    A new family of protein-based antagonists has been created by researchers that efficiently block the granulocyte-colony stimulating factor receptor (G-CSFR), which is essential for the development of leukaemia and other inflammatory illnesses. This groundbreaking work paves the way for targeted therapies that could revolutionise treatment options for patients suffering from these conditions.

  • Press release - 03/01/2025

    Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

  • Press release - 13/12/2024

    Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.

  • Dossier: Innovative animal-free research in Baden-Württemberg - 05/12/2024

    Farewell to animal testing? Life sciences researchers in BW are pioneering innovative methods to replace animal experiments, reduce the number of animals used and refine the procedures and conditions under which animals are kept. These are the guiding principles of the 3Rs principle. Developing cutting-edge models and establishing a robust 3R network, not only shapes the future of research but also improves the quality of scientific outcomes.

  • Press release - 04/12/2024

    The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

  • NMI spin-off develops theranostics - 02/12/2024

    Certain types of cancer are already being effectively treated using immunotherapies, though success rates can vary significantly between patients. Researchers from the Natural and Medical Sciences Institute (NMI) in Reutlingen, along with colleagues at the University of Tübingen, are working on a diagnostic approach to accompany therapy, which would rapidly assess whether the treatment is effective or requires adjustment.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/biotech